Trial reportLasers in medical science2026
`Effect of adjunctive antimicrobial photodynamic therapy on periapical healing and IL-6 modulation in apical periodontitis: a pilot randomized controlled study.
Trial report in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apical periodontitis (AP) is characterized by elevated IL-6 levels and periapical bone resorption. Antimicrobial photodynamic therapy (aPDT) is a promising adjunct to sodium hypochlorite (NaOCl) in root canal disinfection. This pilot randomized controlled trial evaluated the effect of adjunctive aPDT on IL-6 modulation and periapical healing in AP. This 11-month, parallel two-arm pilot randomized controlled study was conducted in a tertiary care hospital in North India (February–December 2024). Participants of AP, aged 18–40 years with single-rooted teeth, were randomized (1:1) to Group A (NaOCl disinfection) or Group B (adjunctive aPDT). The primary outcome was change in IL-6 levels (serum, GCF) from baseline to 6 months. Secondary outcomes were symptom resolution and radiographic healing (CBCT-PAI). Of 44 patients screened, 34 were randomized (17 per group). Two participants in the aPDT group were lost to follow-up. At 6 months, change in IL-6 levels was similar in serum (–0.09 ± 0.71 pg/ml vs. − 0.11 ± 0.70 pg/ml; p = 0.230) and GCF (0.01 ± 0.01 vs. − 0.01 ± 0.06 pg/ml; p = 0.551). Median CBCT-PAI scores were lower in the aPDT group [4 (3–5) vs. 3 (2–4); p = 0.014], with significance maintained on ITT analysis (p = 0.045). Both groups showed comparable symptom resolution. Adjunctive aPDT was comparable to NaOCl alone for IL-6 modulation and symptom relief but demonstrated superior radiographic healing. As a pilot trial, these findings provide preliminary evidence; larger definitive studies are warranted.Trial registration: Clinical Trials Registry-India identifier: CTRI/2024/02/062262.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.